About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2/3NCT00125879

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells...

Lead sponsor: Genzyme, a Sanofi Company•6 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Genzyme, a Sanofi Company

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The patient's legal guardian(s) must provide written informed consent prior to any study-related procedures being performed
•The patient and his/her legal guardian(s) must have the ability to comply with the clinical protocol
•The patient must have completed Protocol AGLU01602.

Exclusion Criteria

•Patient has experienced any unmanageable adverse event (AE) in Protocol AGLU01602 due to Myozyme that would preclude continuing treatment with Myozyme

Related studies

RECRUITINGPhase 4

China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD

NCT06666413 · Glycogen Storage Disease Type II, Pompe's Disease

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

NCT07136844 · Neuromuscular Diseases, Obesity (Disorder), and more

French Observatory for Patients with Type 3 Glycogenosis

NCT06616545 · Glycogen Storage Disease Type III

Active Not RecruitingPhase 1/2

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

NCT04093349 · Pompe Disease, Pompe Disease (Late-onset), and more

TERMINATEDPhase 1/2

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

NCT04990388 · Glycogen Storage Disease Type III

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 6, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2/PHASE3

Enrollment16

Start dateJun 2005

Last updatedFeb 6, 2014

Condition

Glycogen Storage Disease Type II

Locations shown

University of Alabama

Birmingham, Alabama

Shands Hospital at the University of Florida

Gainesville, Florida

Miami Children's Hospital

Miami, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2014Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions